valsartan has been researched along with Adverse Drug Event in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Jones, AM; Salim, H | 1 |
| Horii, N; Inoue, N; Kobayashi, D; Mutoh, M; Negishi, A; Numajiri, S; Ohshima, S; Oshima, S | 1 |
| Kario, K; Kurose, Y; Matsuda, S; Nagahama, S; Sugii, H; Suzuki, N; Teshima, T; Wakabayashi, M | 1 |
| Chen, C; Fang, C; Huang, Y; Ma, L; Zhang, Y; Zhou, H | 1 |
| Aizenberg, D; Chen, CW; Cheung, DG; Gorbunov, V; Hafeez, K; Zhang, J | 1 |
| Jang, K; Lee, H; Lee, J; Lim, KS; Shin, D; Yu, KS | 1 |
| Akpek, M; Avcil, M; Kantekin, B; Kapçı, M; Yavaşoğlu, I | 1 |
| Hafeez, K; Kario, K; Sun, N; Supasyndh, O; Zhang, J | 1 |
| Chrysant, SG; Dattani, D; Hoppe, UC; Murray, AV; Patel, S; Ritter, S; Zhang, J | 1 |
| Curt, V; Hao, YM; Huang, J; Sun, NL; Tu, Y; Zhang, Y; Zhu, JR | 1 |
| Bakris, GL; Cao, C; Handley, A; Kupfer, S; Perez, A; Sica, D; Weber, MA; White, WB | 1 |
| Grosso, A; Kadwa, M; Litwin, M; Pezous, N; Schaefer, F; Turi, S; Zachwieja, J; Zurowska, A | 1 |
| Chang, KC; Chen, IC; Chen, ZC; Hou, CJ; Hsu, KL; Huang, CH; Hung, YJ; Lee, JD; Lei, MH; Liao, PY; Liou, CW; Wang, J; Yeh, TC | 1 |
1 review(s) available for valsartan and Adverse Drug Event
| Article | Year |
|---|---|
Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Valsartan; Young Adult | 2021 |
8 trial(s) available for valsartan and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Drug Combinations; Drug Monitoring; Drug Resistance; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers.
Topics: Adult; Cross-Over Studies; Dihydropyridines; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Healthy Volunteers; Humans; Male; Tetrazoles; Valine; Valsartan; Young Adult | 2014 |
Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension.
Topics: Adult; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Biphenyl Compounds; Blood Pressure; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypertension; Incidence; Male; Middle Aged; Patient Safety; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amides; Antihypertensive Agents; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fumarates; Humans; Hydrochlorothiazide; Hypertension; Incidence; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Young Adult | 2010 |
Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Calcium Channel Blockers; China; Double-Blind Method; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypertension; Korea; Male; Middle Aged; Tetrazoles; Thailand; Treatment Outcome; Valine; Valsartan; Young Adult | 2011 |
Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.
Topics: Age Factors; Aged; Antihypertensive Agents; Benzimidazoles; Biological Availability; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypertension; Male; Middle Aged; Oxadiazoles; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Drug-Related Side Effects and Adverse Reactions; Enalapril; Female; Humans; Hypertension; Male; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Efficacy and safety of valsartan in hypertensive Taiwanese patients: post-marketing surveillance study.
Topics: Aged; Antihypertensive Agents; Asian People; Blood Pressure; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypertension; Male; Middle Aged; Product Surveillance, Postmarketing; Taiwan; Tetrazoles; Valine; Valsartan | 2011 |
8 other study(ies) available for valsartan and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions.
Topics: Adverse Drug Reaction Reporting Systems; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug-Related Side Effects and Adverse Reactions; Excipients; Humans; Neoplasms; Retrospective Studies; Valsartan | 2022 |
Possibility of Multiple Drug-Drug Interactions in Patients Treated with Statins: Analysis of Data from the Japanese Adverse Drug Event Report (JADER) Database and Verification by Animal Experiments.
Topics: Adverse Drug Reaction Reporting Systems; Allopurinol; Animal Experimentation; Animals; Databases, Factual; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Rats; Rhabdomyolysis; Valsartan | 2022 |
A post-marketing survey evaluating the safety and efficacy of a fixed-dose single-pill combination of cilnidipine and valsartan in patients with hypertension: Real-world JSH 2014 and 2019 implementations.
Topics: Aged; Antihypertensive Agents; Blood Pressure Determination; Dihydropyridines; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypertension; Japan; Male; Product Surveillance, Postmarketing; Valsartan | 2020 |
Simultaneous Use of Intravenous Lipid Emulsion and Plasma Exchange Therapies in Multiple Drug Toxicity.
Topics: Amisulpride; Antihypertensive Agents; Antipsychotic Agents; Aripiprazole; Diazepam; Drug-Related Side Effects and Adverse Reactions; Fat Emulsions, Intravenous; Female; Humans; Hypnotics and Sedatives; Hypotension; Middle Aged; Paliperidone Palmitate; Plasma Exchange; Suicide, Attempted; Sulpiride; Treatment Outcome; Turkey; Valsartan | 2016 |